Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23806654 | 1.00 | LMNA (0.40) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL24672378 | 1.00 | LMNA (0.40) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL24851514 | 0.90 | LMNA (0.38) | LMNA | |
| SCHEMBL25123075 | 0.89 | ALDH1A1 (0.32) | LMNA | |
| SCHEMBL4789282 | 0.84 | SIGMAR1 (0.31) | LMNA | |
| SCHEMBL14829803 | 0.80 | TSHR (0.39) | LMNA | |
| SCHEMBL23710842 | 0.80 | LMNA (0.43) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL22861696 | 0.80 | LMNA (0.43) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL21106768 | 0.80 | LMNA (0.43) | LMNAKDM4CKDM4APHF8KDM2A | |
| SCHEMBL21401388 | 0.80 | LMNA (0.43) | LMNAKDM4CKDM4APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | LMNA 321/4885KDM4C 2747/4885KDM4A 2712/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | LMNA 2448/4885KDM4C 690/4885KDM4A 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.